Citric acid/lactic acid/potassium bitartrate - Evofem

Drug Profile

Citric acid/lactic acid/potassium bitartrate - Evofem

Alternative Names: Acidform; Amphora; Amphora contraceptive vaginal gel

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Evofem
  • Developer Evofem Biosciences
  • Class Anti-infectives; Contraceptives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pregnancy
  • Phase I Bacterial vaginosis

Most Recent Events

  • 07 Aug 2017 Evofem complets a phase I trial for Bacterial vaginosis (Prevention) in USA (Vaginal, Gel) (NCT02693418)
  • 27 Jul 2017 Evofem Biosciences initiates enrolment in the phase III AMPOWER trial for Pregnancy (Prevention) in USA
  • 29 Jun 2017 Citric acid/lactic acid/potassium bitartrate - Evofem receives Qualified Infectious Disease Product status for Bacterial vaginosis (Prevention) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top